Revive Therapeutics Ltd. (TSX-V:RVV) (OTCQB:RVVTF)
(FSE:31R)
(“Revive”), a company focused on the
research, development and commercialization of novel
cannabinoid-based therapies, and
WeedMD Inc.
(TSX-V:WMD) (OTC:WDDMF) (FSE:4WE) (“
WeedMD”), a
federally-licensed producer and distributor of medical cannabis,
are pleased to announce they have entered into medical cannabis
research and development supply and collaboration agreements (the
“
Agreements”).
Under the Agreements, WeedMD will supply Revive
with cannabidiol (“CBD”) for the research program evaluating CBD in
the treatment of liver disease, specifically non-alcoholic
steatohepatitis (“NASH”) and autoimmune hepatitis (“AIH”). Working
alongside Revive, WeedMD will support the research, development and
potential commercialization of CBD in the treatment of liver
disease. Additionally, Revive and WeedMD will identify
opportunities for developing and commercializing medical cannabis
products and therapies for potential collaboration in other
treatments. “The relationship with WeedMD represents a significant
milestone for Revive as we have secured a strategic supply of
medical-grade CBD for our research, development and
commercialization efforts for liver diseases,” said Fabio
Chianelli, President of Revive. “With WeedMD’s commitment to
the research, development and commercialization of medical grade
cannabis, they are the ideal strategic partner for Revive to
accelerate the execution of our business plan in commercializing
novel cannabinoid-based therapies and to validate our commercial
development efforts in the medical cannabis market.”
“WeedMD continues to push ahead with its
research and development initiatives, both independently and with
research institutions to accelerate cannabinoid applications and
delivery system innovations, in addition to collecting valuable
data about strains and their effects,” said Dr. Luc Duchesne, Chief
Scientific Officer of WeedMD. “Both WeedMD and Revive are making
advances as participants in the pharmaceutical cannabis market
which begins with the validation of new products and innovations
through clinical-evidence and the establishment of intellectual
property.”
Having recently secured the intellectual
property for its own delivery systems, Revive has assembled a
diversified pipeline of pharmaceutical, prescription, and over the
counter (OTC) products and together with WeedMD, they will evaluate
the efficacy of CBD in the treatment of NASH and AIH, in addition
to other potential indications in the future.
About WeedMD Inc.
WeedMD Inc. is the publicly-traded parent
company of WeedMD Rx Inc., a federally-licensed producer and
distributor of medical cannabis and cannabis oil under the Access
to Cannabis for Medical Purposes Regulations (“ACMPR”). WeedMD
operates a 26,000 sq. ft. indoor facility in Aylmer, Ontario, and a
second-site greenhouse cultivation facility located in Strathroy,
Ontario, representing 610,000 sq. ft. or 14 acres under glass.
WeedMD has entered into supply agreements in addition to strategic
relationships with established cannabis brands.
WeedMD is focused on providing medical cannabis
to the seniors’ market in Canada through its specialized and
comprehensive platform. It is dedicated to educating healthcare
practitioners and furthering public understanding of the role that
medical cannabis plays - including as it pertains to regulatory
requirements, indications and potential side effects.
For more information, access our investor
presentation here and corporate video here.
Follow WeedMD:
https://www.facebook.com/weedmd/https://www.linkedin.com/company-beta/5020743/https://twitter.com/WeedMDhttps://www.instagram.com/weedmd/
About Revive Therapeutics
Ltd.
Revive Therapeutics Ltd. (TSX VENTURE:RVV) (OTCQB:RVVTF) is
focused on the research, development and commercialization of novel
cannabinoid-based therapies. Additional information on Revive
is available at www.ReviveThera.com.
For further information, please
contact:
WeedMD Inc.
Keith Merker, Chief Financial Officer Tel: 519-765-2440 Ext.
222Email: investor@weedmd.com
To learn more, visit us at www.weedmd.com
For Media Inquiries:
Marianella delaBarreraMargin Communications & Public
RelationsTel: 416-897-6644Email: marianella@marginpr.com
Revive Therapeutics Ltd. Craig Leon, Chief
Executive Officer Tel: (416) 272-5525
Email: craig@revivethera.com To learn more, visit us at
www.ReviveThera.com
WeedMD Inc. Forward-Looking
Information
This press release contains forward-looking
information based on current expectations. Statements about the
date of trading of the Company's common shares on the Exchange and
final regulatory approvals, among others, are forward-looking
information. These statements should not be read as guarantees of
future performance or results. Such statements involve known and
unknown risks, uncertainties and other factors that may cause
actual results, performance or achievements to be materially
different from those implied by such statements. The Company
assumes no responsibility to update or revise forward-looking
information to reflect new events or circumstances unless required
by law.
___________________________________________________________________________________________________________________________________________NEITHER
THE TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS
THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE)
ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS
RELEASE
Revive Therapeutics Ltd. Cautionary Note Regarding
Forward-Looking Statements
Neither the TSX-V nor its Regulation Services
Provider (as that term is defined in the policies of the TSX-V)
accepts responsibility for the adequacy or accuracy of this
release.
This news release includes certain information
and statements about management's view of future
events, expectations, plans and prospects that constitute
"forward-looking information" that involves known and unknown risks
and uncertainties, which are not comprised of historical facts, and
most of which are beyond the control of Revive. Forward-looking
statements include estimates and statements that describe Revive’s
future plans, objectives or goals, including words to the effect
that Revive or its management expects a stated condition or result
to occur. Forward-looking statements may be identified by such
terms as "believes", "anticipates", "intends", "expects",
"estimates", "may", "could", "would", "will", or "plan", and
similar expressions. Specifically, forward-looking statements in
this news release include, without limitation, statements
regarding: Revive’s cannabis research and development supply
agreement with WeedMD; Revive’s Collaboration Agreement for Medical
Cannabis Products and Therapies with WeedMD; Revive’s drug research
and development, and commercialization plans; Revive’s research,
development and commercialization plans for plant-based therapies,
including cannabinoids; Revive’s cannabinoid delivery technology;
Revive’s license agreement with Wisconsin Alumni Research
Foundation; Revive’s cannabinoid-based product pipeline; the
timing of operations; and estimates of market conditions. These
statements involve known and unknown risks, uncertainties, and
other factors that may cause actual results or events, performance,
or achievements of Revive to differ materially from those
anticipated or implied in such forward-looking statements. Since
forward-looking statements are based on assumptions and address
future events and conditions, by their very nature they involve
inherent risks and uncertainties. Revive believes that the
expectations reflected in these forward-looking statements are
reasonable, but there can be no assurance that actual results will
meet management's expectations. In formulating the forward-looking
statements contained herein, management has assumed: that business
and economic conditions affecting Revive will continue
substantially in the ordinary course and will be favourable to
Revive; that clinical testing results will justify
commercialization of the Revive’s drug candidates; that Revive will
be able to obtain all requisite regulatory approvals to
commercialize its drug candidates; that such approvals will be
received on a timely basis; and, that Revive will be able to find
suitable partners for development and commercialization of its drug
repurposing candidates on favourable terms. Although these
assumptions were considered reasonable by management at the time of
preparation, they may prove to be incorrect and no assurance
can be given that such events will occur in the disclosed time
frames or at all.
Factors that may cause actual results to differ
materially from those anticipated by these forward-looking
statements include: uncertainties associated with obtaining
regulatory approval to perform clinical trials and market products;
the need to establish additional corporate collaborations,
distribution or licensing arrangements; Revive’s ability to raise
additional capital if and when necessary; intellectual property
disputes; increased competition from pharmaceutical and
biotechnology companies; changes in equity markets, inflation, and
changes in exchange rates; and other factors as described in detail
in Revive's Management's Discussion & Analysis for the period
ended June 30, 2017 and Revive's other public filings, all of which
may be viewed on SEDAR (www.sedar.com). Given these risks and
uncertainties, readers are cautioned not to place undue reliance on
such forward-looking statements and information, which are
qualified in their entirety by this cautionary statement. Except as
required by law, Revive disclaims any intention and assumes no
obligation to update or revise any forward-looking statements to
reflect actual results, whether as a result of new information,
future events, changes in assumptions, changes in factors affecting
such forward-looking statements or otherwise.
WeedMD (TSXV:WMD)
Historical Stock Chart
From Aug 2024 to Sep 2024
WeedMD (TSXV:WMD)
Historical Stock Chart
From Sep 2023 to Sep 2024